Showing 5891-5900 of 9770 results for "".
- Melanoma Survival Rates Lower in Patients with Skin of Colorhttps://practicaldermatology.com/news/melanoma-survival-rates-lower-in-patients-with-skin-of-color/2458482/Although patients with skin of color are less likely to develop melanoma than caucasian patients, they have a higher rate of mortality from the disease, new research shows. Writing in the Jounral of the A
- Mission Pharmacal Expands Dermatology Commitment with the Acquisition of GlyDermhttps://practicaldermatology.com/news/mission-pharmacal-expands-dermatology-commitment-with-the-acquisition-of-glyderm/2458487/Espada Dermatology, Inc, a wholly-owned subsidiary of Mission Pharmacal Company, purchased the GlyDerm line of skin care products from Lautus Pharmaceuticals, LLC. Prior to this acquisition, Mission offered prescription dermatological products solely through Mission Dermatology
- FDA Cracks Down on Mercury in Anti-Aging Productshttps://practicaldermatology.com/news/fda-cracks-down-on-mercury-in-anti-aging-products/2458488/The U.S. Food and Drug Administration is re-issuing a warning about the dangers of mercury in skin creams, beauty and antiseptic soaps, and lotions. In the past few years, the FDA and state health officials
- Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelengthhttps://practicaldermatology.com/news/syneron-candelas-picoway-picosecond-laser-receives-us-fda-clearance-for-ultra-short-785nm-wavelength/2458489/And then there were three. The U.S. Food and Drug Administration (FDA) has cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for a new ultra-short 785nm wavelength. The addition of the new
- ISDIN Launches in the UShttps://practicaldermatology.com/news/isdin-launches-in-the-us/2458501/Barcelona-based ISDIN is officially operating in the US. The company—which operates in Europe, Latin America, and Asia—is bringing its skincare products to the US market. ISDIN’s portfolio of over-the-counter products target
- Cynosure Receives Health Canada Authorization to Market SculpSure®https://practicaldermatology.com/news/cynosure-receives-health-canada-authorization-to-market-sculpsure/2458503/Cynosure, Inc. received Health Canada Authorization to Market SculpSure® for non-invasive lipolysis of the abdomen and flanks. SculpSure is a fat-reduction laser intended for individuals with a body mass index (BMI) of 30 or less. The
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme
- UCB: Investigational Bimekizumab Helps Psoriatic Arthritis in Phase 1Bhttps://practicaldermatology.com/news/ucb-investigational-bimekizumab-helps-psoriatic-arthritis-in-phase-1b/2458534/Bimekizumab, in development by UCB, has shown promise for the treatment of psoriatic arthritis (PsA) in Phase 1B studies. For the study, a total of 52 PsA patients inadequately controlled with at least one disease-modifying anti-rheumatic drug (DMARD) and/or one biologic were randomized to
- Solta Medical Launches Consumer Campaign to Empower LGBTQ Communityhttps://practicaldermatology.com/news/solta-medical-launches-consumer-campaign-to-empower-lgbtq-community/2458538/Solta Medical, a division of Valeant Pharmaceuticals North America LLC, is supporting the LGBTQ community through a focused consumer campaign that will help shed one more layer to reveal one’s true self. In addition, Solta Medical was the exclusive medical aesthetic category sponsor of the
- GlobalMed Technologies Acquires Omnilux Medicalhttps://practicaldermatology.com/news/globalmed-technologies-acquires-omnilux-medical/2458551/GlobalMed Technologies (GMT) has acquired Omnilux Medical, the gold standard for medical and aesthetic Light Emitting Diode (LED) skincare. The asset acquisition includes three Omnilux Medical Systems, the Omnilux Revive2™, Omnilux Blue™ and Omnilux Plus™,